DESTINY-Breast12
Enhertu shrank brain metastases in most patients, including those with untreated lesions, answering a question its earlier trials had excluded.
Phase 3b/4, 263 patients with brain metastases: 12-month PFS 61.6%; CNS ORR 71.7% overall (82.6% in active/untreated brain metastases). Supports T-DXd as a systemic option for brain metastases rather than local therapy first in selected patients.
- 71.7 out of 100 people had their tumour shrink with T-DXd (brain metastasis cohort).
- There was no comparison group, so this number cannot tell you how much of the effect is due to the treatment.
- A response rate counts how many people had their tumours shrink by a set amount; shrinking is encouraging but does not by itself show that people live longer or feel better.
- These results apply to the people the trial enrolled: HER2+ metastatic breast cancer with or without brain metastases: single-arm T-DXd. People in a different situation may not see the same effect.
- The trial selected people by a biomarker (HER2); the result should not be assumed for people whose cancer does not have it.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
504 participants enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Intracranial objective response rateprimary | T-DXd (brain metastasis cohort) | 263 | 71.7% | — | — | link |
Pages like this
not linked directly; found by shared links- TrialHER2CLIMB
Shares Systemic-first management of HER2-positive brain metastases, HER2-positive brain metastases, The brain: barrier and sanctuary, HER2-positive breast cancer.
- IdeaUse the brain's own transport door to carry antibody drugs across
Shares HER2-positive brain metastases, The brain: barrier and sanctuary, Trastuzumab deruxtecan, HER2-positive breast cancer.
- PairingTucatinib + trastuzumab + capecitabine for brain metastases
Shares HER2-positive brain metastases, HER2-positive breast cancer.
- IdeaDeliver CAR-T cells straight into the fluid around the brain
Shares HER2-positive brain metastases, The brain: barrier and sanctuary, HER2-positive breast cancer.
- IdeaBrain metastases included by default in every solid-tumour trial
Shares The brain: barrier and sanctuary, Trastuzumab deruxtecan, HER2-positive breast cancer.
- ProductTrastuzumab duocarmazine
- ProductNeratinib
Shares HER2-positive brain metastases, HER2-positive breast cancer.
- IdeaStop excluding brain metastases from cancer trials
Shares HER2-positive brain metastases, The brain: barrier and sanctuary.